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ABSTRACT

The ability for species to evolve new features in response to changing circumstances in order to
survive and propagate is a ubiquitous observation on both the macroscopic and microscopic
levels of living systems. It should be no surprise, then, that diseases such as cancer utilize their
own forms of adaptation to perpetuate themselves when exposed to external threats. Indeed,
concepts drawn from Darwinian evolution are now widely accepted to help explain certain
aspects of carcinogenesis and malignant progression, the sum of which have come to be known
as the theory of tumor evolution. Since metastasis and drug resistance are features that manifest
toward the late stages in the disease after withstanding numerous selective pressures, cancer cells
harboring these features can be viewed as the most evolutionarily fit. Just as many forms of life
rely on common adaptive mechanisms to promote their survival during dramatic shifts in their
environment, metastatic and drug resistant cancers may rely upon common cellular mechanisms
to promote their survival when faced with untenable circumstances. We hypothesize that one of
the oldest genes in the human genome, HSP90, functions as a link between metastatic and drug
resistant behavior of cancer. We believe this occurs through HSP90’s relationship in supporting
the function of gene products that define the cancer hallmarks and clinical evidence suggesting
HSP90 is important in progressing cancer into advanced stages. In the following chapters we
discuss HSP90 and its role in orchestrating evolution of metastatic and drug resistant phenotypes.
We use the clinically relevant HSP90 inhibitor, AUY922, to explore our assertions in vitro in the
context of non-small cell lung cancer (NSCLC), which is prone to evolving metastatic and drug
resistant phenotypes. We examine the implications for our findings, future directions, and new
possibilities for utilizing HSP90 inhibitors to treat cancer.
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CHAPTER 1: INTRODUCTION

Heat shock protein 90 (HSP90) is among some of the most primordial and well conserved
genes in the human genome (Schlesinger, 1990). It has retained its function in all of eukarya,
from yeast to humans, with homologs in numerous prokarya as well. Despite its age in the
genomes of almost every organism on earth, it has only been in the last 60 years that we have
been able to study it in any sort of detail. Early studies taught us that HSP90 is necessary in order
to maintain viability in eukaryotic cells (Picard, 2002), indicating that evolution has placed a
high priority in preserving its function over the millennia. However, the dependence eukaryotic
cells have on HSP90 to maintain function has made it difficult to study, as genetic manipulation
of HSP90 usually results in cells and organisms that are hypersensitive to heat stress (Picard,
2002). This has been a significant barrier to understanding what, if any, relevance HSP90 has to
medicine. At the very minimum, these observations delineated HSP90’s role in managing
stressful stimuli, with further research describing HSP90 as essential in managing various forms
of cellular stress other than heat stress (Courgeon, Maisonhaute, & Best-Belpomme, 1984;
Heikkila, Schultz, Iatrou, & Gedamu, 1982; Michel & Starka, 1986; Yura, Tobe, Ito, & Osawa,
1984).
Since the 1970’s, it has been possible to target HSP90 pharmacologically (DeBoer,
Meulman, Wnuk, & Peterson, 1970), making it easier to interrogate its function without severely
compromising biological systems. Decades of research manipulating HSP90 pharmacologically
have produced some surprising revelations. One of the most interesting patterns of discovery has
been that drugging HSP90 can generate unexpected, novel phenotypes at the single cell and
whole organism levels (Lawag et al., 2017; Queitsch, Sangster, & Lindquist, 2002; Rohner et al.,
2013; Sollars et al., 2003). Some of these phenotypes are somewhat disjointed and would have
1

little chance in helping the organism achieve success in a natural setting subject to the forces of
Darwinian evolution. This suggests that HSP90 may be important in reinforcing phenotypes that
will promote the fitness of organisms in their environment, especially under stressful conditions.
It is now widely accepted that the genetic, epigenetic, and phenotypic changes that
cancers accrue can be explained by concepts pulled from Darwinian evolution, a theory known
as tumor evolution (Casas-Selves & Degregori, 2011; Greaves, 2015; Lacina et al., 2019). The
phenotypes malignant tumors evolve in the advanced stages of the disease can be viewed as the
most fit since these cells survived late into the disease process. In the late stages of cancer, these
phenotypes almost always result in metastatic and drug resistant behavior. If HSP90 is important
in reinforcing fitness in species, then it is possible that HSP90 may be reinforcing fitness of
cancers, in particular, fitness coupled to metastasis and drug resistance. Interestingly, HSP90
inhibitors have also demonstrated potent and specific anticancer effects in a variety of tumors.
In the following chapters, we discuss HSP90’s role in the heat shock response, and posit
in what way HSP90 is essential in perpetuating the evolution of metastatic and drug resistant
phenotypes in cancer. We will support our claims with scientific evidence demonstrating
pharmacological inhibition of HSP90 attenuates metastatic and drug resistant phenotypes in
vitro. We will close by examining the implications of this evidence, future directions, and
considering novel ways to use HSP90 inhibitors to improve cancer treatment outcomes.
The Heat Shock Response
Organisms are exposed to a plethora of environmental insults that threaten cellular
homeostasis and rely on cellular programs that respond promptly to these stressors to maintain
normal cell functions. One of the most ancient and evolutionarily conserved responses to stress
found in all of eukarya on earth is the heat shock response (Ritossa, 1996; Schlesinger, 1990).
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An increase in just a few degrees can cause proteins to denature, become entangled, and
aggregate within a cell. This disruption of proteostasis signals a dramatic increase in the
production of a class of proteins known as heat shock proteins (HSPs) (Lindquist, 1986).
Members of this class include HSP100, HSP90, HSP70, HSP60, and HSP40. They function as
molecular chaperones, physically interacting with and manipulating misfolded, unstable and
damaged proteins in order to aid them in reaching a mature conformation, ultimately maintaining
appropriate trafficking, signaling integrity, and degradation of proteins in the face of heat stress.
Proteins that rely on HSPs to maintain their native conformation are referred to as clients, with
some HSPs having very specific clientele while others, such as HSP90, chaperone hundreds of
clients stretching across multiple, indispensable cellular processes. Further research revealed that
other forms of stress, such as hypoxia, acidosis, and chemical damage also result in disruption of
proteostasis and up regulation of HSPs (Courgeon et al., 1984; Heikkila et al., 1982; Michel &
Starka, 1986; Yura et al., 1984). Since other forms of stress can up regulate HSPs, the heat shock
response has also come to be known as the “stress” response. When the source of stress is
removed, HSPs return to their basal state, but remain primed to increase when faced with stress
in the future.
The wide range of gene products in essential cell processes engaged by HSPs during
stressful stimuli codifies the heat shock response as an adaptive mechanism, functioning
primarily to maintain smooth cellular function in the face of stress. This has obvious benefits in
that all biological tissues are likely to experience stress at some point in time, so having access to
mechanisms permitting the cell to adapt to stress is critical to maintaining tissue integrity.
Unfortunately, the heat shock response can enable certain diseases such as cancer. Indeed,
numerous studies have demonstrated elevated HSP expression in a variety of human cancers
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(Calderwood, Khaleque, Sawyer, & Ciocca, 2006; Sherman & Multhoff, 2007). This should not
be surprising as one of the overarching themes in cancer is the acquisition of mutations resulting
in unstable gene products that require additional processing by HSPs in order to function.
Furthermore, many of the stressful stimuli associated with induction of HSPs also occur in
cancer. For example, the accelerated growth and proliferation of neoplastic tissue can promote
the formation of lactic acidosis in the tumor microenvironment. Additionally, application of high
dose chemotherapy to treat cancer can be expected to supply the chemical stress necessary to
induce HSP expression (Tiligada, 2006). Of the HSPs implicated in driving oncogenic processes,
HSP90 is considered unique as it has distinct characteristics that separate it from other HSPs.
Additionally, HSP90 may function differently in neoplastic tissue relative to normal tissue.
HSP90
Vertebrates retain two isoforms of HSP90, HSP90α and HSP90β. HSP90α is considered
the inducible isoform, and its expression increases when a cell is exposed to stressful stimuli.
HSP90β operates in a constitutive fashion, and is widely expressed at basal conditions (Millson
et al., 2007). HSP90α and HSP90β share 86% sequence homology (Langer & Fasold, 2001) and
are thought to be derived from a gene duplication event 500 million years ago (Krone & Sass,
1994). HSP90 is almost exclusively found in the cytoplasm, although evidence is accumulating
that it functions in the nucleus as well (Calderwood & Neckers, 2016), leaving open the
possibility HSP90 directly influences transcriptional changes and epigenetic mechanisms, in
addition to its classical chaperone function (Lawag et al., 2017; Sollars et al., 2003). It forms a
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Figure 1. HSP90 Chaperone Function
(A) Illustration of the three functional domains of HSP90, N=N terminal domain, M=middle
domain, C=C terminal domain. The N terminal domain containing the nucleotide binding pocket
in latent HSP90 has low affinity for ATP or small molecule HSP90 inhibitors (blunt ends). The
C terminal domain is necessary for dimerization. (B) Upon binding to co-chaperones that aid in
presentation of the unstable protein client to the active site, HSP90 achieves an activated
conformation with high affinity for small molecule HSP90 inhibitors (top) (indicated by notch in
N-terminal domain) and for ATP (bottom). (C)(Top) In the presence of small molecule
inhibitors, HSP90 cannot complete chaperone function and client protein cannot achieve mature
conformation, leading to proteosomal degradation and breakdown of essential cell functions
during stress. (Bottom) ATP hydrolysis drives “pincer” mechanism, which assists client proteins
in successfully reaching a mature conformation under stress.
dimer at physiological temperatures and contains an N-terminal domain, a middle-domain and a
C-terminal domain (Figure 1A). HSP90 is ATP dependent and contains a nucleotide-binding

5

pocket belonging to the GHKL family in its N-terminal domain (Prodromou et al., 1997). This
ATP binding pocket is distinct from other chaperones and kinases and is the target of small
molecule HSP90 inhibitors (Figure 1B). The middle domain contains the binding site for clients
and for co-chaperones that assist HSP90 in its chaperone function (Hawle et al., 2006). The Cterminal domain is necessary for HSP90 dimerization (Harris, Shiau, & Agard, 2004; Minami,
Kimura, Kawasaki, Suzuki, & Yahara, 1994; Nemoto, Ohara-Nemoto, Ota, Takagi, &
Yokoyama, 1995) and also binds certain clients. These three domains work in concert with cochaperones to manipulate unstable proteins into a functional, active conformation (Figure 1).
When HSP90 is bound to co-chaperones containing an unstable protein in need of achieving a
mature conformation, it is referred to as “activated” HSP90 (Kamal & Burrows, 2004). This state
is found in stressed tissues and cancer cells, and is the state in which HSP90 is most receptive to
pharmacological inhibition. HSP90 not bound to clients and co-chaperones is known as “latent”
HSP90 (Kamal & Burrows, 2004). The latent form of HSP90 is commonly found in normal,
unstressed tissues.
Unlike other HSPs, HSP90 is essential in all eukaryotes and is present in large excess,
representing 1-2% of a cell’s total proteome in unstressed conditions (Borkovich, Farrelly,
Finkelstein, Taulien, & Lindquist, 1989; Taipale et al., 2012; Taipale et al., 2014). Excess HSP90
expression in unstressed tissues is thought to provide a buffer for cells to quickly manage
transient levels of incoming proteotoxic stress. HSP90 also engages its clients differently than its
HSP cousins. Other HSPs interact with their clients transiently while many clients associated
with HSP90, such as steroid hormone receptors, require continuous interaction in order to
maintain a functional conformation (Pratt & Toft, 1997). Additionally, while HSP90 has
hundreds of clients, they tend to focus around kinases, signal transducers, and transcription
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factors that are key nodes to an assortment of cell signaling and developmental pathways
(Taipale, Jarosz, & Lindquist, 2010; Taipale et al., 2014). Therefore, mechanisms that limit
HSP90 function may have substantial effects on a cell’s behavior and ability to manage exposure
to stressful stimuli.
Perhaps the most profound aspect of HSP90 is its influence on rapid acquisition of novel
traits through its role as both a potentiator and capacitor of phenotypic variation, at both the
single cell and whole organism levels. As a potentiator of phenotypic variation, HSP90 can use
its chaperone function to properly fold and support the function of unstable signal transducers,
influencing phenotypic switches that can occur from selective pressures downstream of these
signal transducers. For example, calcineurin relies on HSP90 to function (Imai & Yahara, 2000;
Kumar, Musiyenko, & Barik, 2005), and studies involving yeast showed calcineurin requires
HSP90 in order to promote rapid acquisition of resistance to antifungal drugs (Cowen &
Lindquist, 2005). As a capacitor of phenotypic variation, HSP90 chaperone activity can mask
phenotypic variation associated with cryptic genetic alterations in a cell or organism until
extreme stresses or small molecule inhibition of HSP90 overwhelm its chaperone function and
reveals them (Lawag et al., 2017; Queitsch et al., 2002; Rohner et al., 2013; Sangster et al., 2007;
Sollars et al., 2003). This is the setting in which phenotypes with apparent decreases in
evolutionary fitness have been observed (Queitsch et al., 2002; Sangster et al., 2007; Sollars et
al., 2003). In fact, reductions in fitness were directly observed through reduced number of seeds
produced by A. thaliana plants with attenuated HSP90 function (Sangster et al., 2007). Taken
together, one would expect HSP90’s dual role as a potentiator and capacitor of novel phenotypes
to have a measurable effect on the emergence of new phenotypes in a setting subject to the rules
of Darwinian evolution, such as cancer.
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Tumor Evolution, Intratumoral Heterogeneity, and HSP90
Applying the concept of Darwinian evolution to cancer is not a cutting edge idea
(Nowell, 1976), but it was not until the last few decades that technological advances have
permitted researchers to study cancer at the level of detail necessary to build a strong case that
concepts pulled from Darwinian evolution can explain certain aspects of carcinogenesis (CasasSelves & Degregori, 2011; Greaves, 2015; Lacina et al., 2019). On a fundamental level, cancers
evolve over time because they fulfill the three conditions of Darwinian evolution: propagation of
genetic material to the next generation; heterogeneous phenotypes existing in one biological
system; and the existence of selective pressures that act on that heterogeneity so that the fittest
survive.
Fulfillment of all three conditions is exemplified by some of the most basic observations
of neoplastic behavior. Propagation of genetic material is derived from the understanding that
cancer is a clonal disease. As each cancer cell divides, it passes on its genetic material to
daughter cells, thus promulgating the neoplastic phenotype. Metastasis is an example of
heterogeneity developing in a cancer. If a cancer started in one place, and then transplanted to a
distant site, there was a point where the primary tumor became a heterogeneous population of
cancer cells: some willing to migrate to a new tissue landscape, others content on their primary
place of residence. Lastly, decades of clinical observations of remission followed by relapse of
drug resistant cancers is evidence of tumors experiencing, adapting to, and overcoming selective
pressures of therapy over time. The development of chemotherapeutic resistance actually
encapsulates all three Darwinian conditions. After selective pressure of therapy is overcome,
either through intrinsic or acquired resistance mechanisms, surviving cancer cells will again
continue to proliferate, passing on to their progeny the genetic code that permitted resistance to
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occur, which eventually manifests as multidrug resistant relapse (Gatenby & Brown, 2018).
There are other examples of neoplastic behavior that fulfill Darwinian conditions, but metastasis
and drug resistance are highlighted here because they are two consequences of tumor evolution
and two major sources of treatment failure in cancer.
In order to maintain perpetual evolution, the most vital of the Darwinian conditions is the
existence of heterogeneous populations. Without heterogeneity, the potential to change is
substantially constrained, regardless of the ability to propagate genetic material or the presence
of selective pressures. In terms of cancer, this is known as intratumoral heterogeneity (ITH),
which for this discussion refers to the diversity of malignant phenotypes that exist within a tumor
as a product of their various genetic and epigenetic alterations. Numerous sequencing studies of
a range of temporal and spatially distinct tumor types reveal an astounding spectrum of cellular
diversity in any individual patient’s tumor (Bolli et al., 2014; de Bruin et al., 2014; Eckert et al.,
2016; Uchi et al., 2016; Yates et al., 2015; Zhang et al., 2014). This pool of diversity provides
the substrate for Darwinian processes to test and select the most advantageous malignant
phenotypes to withstand the stresses of genetic alterations, microenvironmental pressures, energy
demands, and cytotoxic therapy that cancer cells eventually experience. ITH has also been linked
to development of metastasis and drug resistance (Bhang et al., 2015; Hallou, Jennings, & Kabla,
2017; Piotrowska et al., 2015; Wei et al., 2017), making the formation of heterogeneous tumor
populations a central component of treatment failure.
The source of ITH in cancer is predominantly derived from cell intrinsic processes that
define the disease. Cancer is typically described in terms of accumulating mutations in the
genetic code that results in protein products that are nonfunctional, severely compromised, or
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Figure 2. Illustration of the Consequences of Genetic Instability or Epigenetic
Modifications on the Formation of Heterogeneous Populations in a Tumor.
The four-pointed star represents the silencing of tumor suppressor genes that sets forth the
cascade of genomic instability and accumulation of oncogenic mutations. As the tumor grows
and clonal progeny accumulate mutations, they may acquire driver mutations (thick lines) that
provide a fitness advantage and changes in their identity (change in color). Tumor cells may also
acquire passenger mutations (thin lines) that change their identity, but offers no additional fitness
advantage. Over time, tumor cells evolve metastatic and drug resistant features.
inappropriately activated. A necessary mutational event that initiates malignant transformation is
the silencing of tumor suppressor genes. These genes function to guard the genome against
accumulation of oncogenic mutations that promote abnormal cellular behavior. If a mutation
occurs in a tumor suppressor gene that renders it nonfunctional, mutations can accumulate
unchecked, ultimately permitting the formation of a neoplastic clone that grows, divides, and
invades surrounding tissue beyond its normal capacity. As the newly transformed clone
10

proliferates into a small group of progeny that also lack tumor suppressor functions as acquired
from their parent, new mutations are permitted to accumulate unrestricted with each cell
division. This process is known as genomic instability and is a major source of genetic ITH in
cancer (Burrell, McGranahan, Bartek, & Swanton, 2013). As incidental mutations amass with
each round of the cell cycle, genotypes begin to diverge from one another, over time forming
trunks and branches that resemble a phylogenetic tree (Figure 2).
Many mutations will be deleterious to neoplastic sub clones, resulting in their rapid
removal from the tumor population. If a mutation occurs in a gene that imparts a fitness
advantage to a cancer cell, this mutation will persist and be passed on to future cellular progeny.
These mutations are known as driver mutations (Vogelstein et al., 2013), and in the context of
branching evolution, represent the trunks and large branches of a cancer’s phylogenetic tree
(Figure 2). They may also acquire passenger mutations, which are supplementary mutations that
occur alongside driver mutations that do not impart any particular selective advantage relative to
surrounding cancer cells. Some evidence suggests passenger mutations may actually become
detrimental if too many accumulate (McFarland, Korolev, Kryukov, Sunyaev, & Mirny, 2013;
Vogelstein et al., 2013). Passenger mutations make up the smallest branches of the phylogenetic
tree. Over time, many trunks and branches may form, generating an array of genotypes that result
in distinct cellular identities and behaviors (Figure 2). Computer models utilizing patient biopsy
data and known driver mutation frequencies support the notion that a wide variety of distinct
genotypes can be derived from a single malignant common ancestor over time (Waclaw et al.,
2015), propelled primarily by genomic instability (Greaves & Maley, 2012).
Diversity in a tumor is not strictly limited to genetic variation. Epigenetic variation is also
abundant in a tumor (Easwaran, Tsai, & Baylin, 2014). Epigenetics refers to changes in gene
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expression without a change in the DNA sequence itself that can be propagated through mitosis
or meiosis. This usually refers to mechanisms regulating chromatin structure such as DNA
methylation or histone modifications. Changes in DNA methylation can operate similar to
mutations in terms of how they influence gene expression, with hypermethylation of CpG islands
leading to gene silencing, and hypomethylation of CpG islands leading to gene activation. For
example, hypermethylation of tumor suppressor genes, such as pRB, can silence its expression
and initiate the formation of a retinoblastoma tumor (Greger, Passarge, Hopping, Messmer, &
Horsthemke, 1989). There are fewer examples of specific oncogene activation through
hypomethylation, however global hypomethylation is a well-documented phenomena in cancer
and may promote an even greater increase in genomic instability since looser chromatin is more
prone to breakage and translocation events (Javadekar & Raghavan, 2015).
If an epigenetic modification commonly results in gene expression changes that confer a
selective advantage, it is referred to as an epi-driver gene (Vogelstein et al., 2013). Epi-driver
genes are analogous to driver mutations, forming the trunk and large branches of a cancer’s
phylogenetic tree. There are two important implications for epigenetic variation in a tumor. The
first is that two genetically identical cancer cells may have different epigenetic signatures, which
may lead them to behave differently. This adds a notable layer of depth to the notion of ITH.
Second, epigenetic modifications are sensitive to the environment and may occur rapidly, much
faster than it could take for driver mutations to become apparent. Rapid epigenetic changes are
thought to be a major cause of acquired drug resistance in cancer (Flinders et al., 2016).
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Figure 3. The Relationship Between Intratumoral Heterogeneity (ITH) and Tumor
Evolution According to the Cancer Hallmarks.
Over time the tumor evolves into three basic phenotypes, each represented by different colors
(orange, purple, pink). The size of the colored boxes represents the relative dependence the clone
has on the corresponding cancer hallmark to maintain its phenotype. Founder mutations begin
the first neoplastic clone (orange). As it divides over time, the progeny may accumulate
mutations or epigenetic changes, and sub clones may form with new abilities. A sub clone may
gain the ability to induce angiogenesis (pink) through secretion of pro-angiogenic factors like
VEGF to establish a blood supply and provide the tumor with additional nutrients. As time
progresses, further changes in gene expression may generate a metastatic sub clone through
activation of cellular programs like EMT (purple) that permit invasion and metastatic spread to
distant sites in the body. Adapted from Hanahan and Weinberg 2000.
Epigenetic modifications also drive transdifferentiation of cancer cells undergoing epithelial to
mesenchymal transition (EMT), eventually resulting in induction of the metastatic cascade
during cancer progression (Tam & Weinberg, 2013).
The concept of ITH makes it appear that cancers evolve new phenotypes in stochastic and
unpredictable ways. However, after decades of research a pattern has taken shape. In 2000,
Hanahan and Weinberg published their seminal work, “Hallmarks of Cancer”(Hanahan &
Weinberg, 2000), in order to sum up and stratify the dizzying array of cellular behaviors that
manifest in tumors. They would later update their analysis of the cancer hallmarks by adding
four emerging hallmarks (Hanahan & Weinberg, 2011), but we will only refer to the original six
13

hallmarks as they have withstood the test of time. The hallmarks of cancer represent a pattern of
discernible neoplastic behaviors driven by mutated gene products (Hanahan & Weinberg, 2000)
and aberrant epigenetic modifications (Easwaran et al., 2014; Flavahan, Gaskell, & Bernstein,
2017). With this said, the cancer hallmarks can be referred to as a cooperative set of phenotypes
selected for according to the theory of tumor evolution. Given what we also know about the
assortment of phenotypes that can exist within a tumor, there are certainly distinct populations
that depend on cancer hallmarks to varying degrees to maintain their survival during the course
of disease progression (Figure 3).
Where does HSP90 fit into this discussion? One of the most interesting aspects of HSP90
is many of its clients are also gene products that define the cancer hallmarks. In fact, if one were
to compare the list of verified HSP90 clients (Picard, 2019) to gene products that drive the
cancer hallmarks (Moser, Lang, & Stoeltzing, 2009), they would discover considerable overlap.
(Figure 4) This relationship has undergone intense investigation and numerous studies report
that HSP90 is essential in promoting the cancer hallmarks, from the acquisition of immortal
characters to the development of metastasis and drug resistance (Kim et al., 2008; Nolan, Franco,
Hance, Hayward, & Isaacs, 2015; Whitesell et al., 2014). Since the hallmarks of cancer represent
a heterogeneous group of features malignant neoplasms are bound to achieve over time, and
HSP90 appears necessary to maintain them, then HSP90 may be promoting ITH by stabilizing
mutated and unstable gene products that delineate the cancer hallmarks through its potentiator
function as a chaperone. Moreover, the large pool of excess HSP90 also serves to steady
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Figure 4. HSP90 and the Cancer Hallmarks
Depiction of the overlap of HSP90 clients with gene products within the hallmarks of cancer.
Adapted from Hanahan and Weinberg 2000.
rapid and widespread changes in gene expression that can occur under the direction of epi-driver
genes. Stated another way, HSP90 may play a fundamental role in supporting the emergence of
various cancer hallmarks and thus, provides the medium by which ITH can manifest, ultimately
setting the table for Darwinian processes to advance tumor evolution and subsequent disease
progression (Figure 5).
The association between HSP90 in supporting ITH and propelling tumor evolution is
further strengthened when one considers the clinical impact HSP90 expression has on a patient’s
cancer. Clinical evidence indicates that increased HSP90 expression is associated with various
cancers and has been linked to a poor clinical prognosis (Flandrin et al., 2008; Pick et al., 2007;
Thomas et al., 2005; Wu, Huang, Liu, & Liu, 2015; Zagouri et al., 2010). High HSP90
expression was associated with increased Her-2/neu and estrogen receptor expression, large
tumors, high nuclear grade, and lymph node involvement in breast cancers (Pick et al., 2007), all
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Figure 5. Unification of HSP90, ITH, and Tumor Evolution According to the Cancer
Hallmarks
Illustration of HSP90 promoting ITH, through simultaneous support of neoplastic sub clones that
depend on cancer hallmarks to varying degrees (orange, pink, and purple circles). The size of the
colored boxes represents the relative dependence the clone has on the corresponding cancer
hallmark to maintain its phenotype, with HSP90 encircling all six original cancer hallmarks
indicating it is supporting the current state of each sub clones cancer hallmarks, but is also poised
to support other cancer hallmarks when a cancer cell may require more dependence. Adapted
from Hanahan and Weinberg 2000.
heterogeneous features that require significant changes in the primary tumor in order to occur. It
is also important to note that both the estrogen and Her2/neu receptors are HSP90 clients. HSP90
over expression in gastric cancer patients correlated with increased depth of invasion, lymph
node involvement, and a higher stage of disease progression (J. Wang, Cui, Zhang, Wu, & Tang,
2013), again a mix of features that necessitate changes within the primary tumor in order to
manifest.
Interestingly, while HSP90 overexpression is strongly linked to poor prognoses in
cancers, HSP90 itself is not mutated in cancer (Workman, Burrows, Neckers, & Rosen, 2007),
suggesting that the native conformation of HSP90 provides a significant fitness advantage to
evolving cancer cells. This fitness advantage may be inherent to HSP90’s ability to support the
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cancer hallmarks, which eventually generates the level of ITH necessary for cancers to evolve to
advanced stages (Bhang et al., 2015; Gainor et al., 2016; Wei et al., 2017). Since HSP90 is not
mutated in most cancers, this also makes it a lucrative target for sustained small molecule
inhibition to potentially limit ITH and restrict tumor evolution.
However, there is one small problem with this assertion. As previously stated, research
suggests that HSP90 can influence phenotypic diversity in two ways. It acts as a potentiator of
phenotypic diversity by using its chaperone activity to support the function of unstable proteins
that rely on HSP90 in order to transfer signals for phenotypic change. HSP90 can also act like a
capacitor for phenotypic diversity by masking the effect of small changes in the genetic code on
proteins through reinforcement of the wild type phenotype, also known as canalization
(Waddington, 1959). As a capacitor, HSP90 stores cryptic phenotypic diversity and only reveals
them when its chaperone function becomes overwhelmed, either through small molecule
inhibition or various forms of extreme stress (Lawag et al., 2017; Rohner et al., 2013; Sollars et
al., 2003). If inhibition of HSP90 can reveal additional phenotypic diversity, and thus contribute
to ITH, how do we reconcile using HSP90 inhibitors to limit tumor heterogeneity and stall a
cancer’s evolution?
The answer may lie in studying some of the effects HSP90 inhibition has on whole
organisms. When HSP90 is inhibited in the small flowering plant, Arapidopsis thaliana, multiple
changes occurred in the plant including organ number defects, deformed leaves, and smaller
quantities of seeds (Queitsch et al., 2002; Sangster et al., 2007). HSP90 inhibition or inactivation
in Drosophila melanogaster produced a population of flies with limb like structures growing out
of the eye that normally was not there (Sollars et al., 2003). In each of these cases, inhibition of
HSP90 during the organisms’ development generated new phenotypes that would not likely
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promote the long-term success of that organism in its natural environment. In other words, they
are less fit than their wild type counterparts. This decrease in fitness was directly postulated in
the study of A. Thaliana (Sangster et al., 2007). The disordered eye phenotype in D.
melanogaster is not likely to result in reproductive success of that fly in an uncontrolled, natural
setting, since finding a mate and avoiding predators is certainly easier with vision completely
intact. Indeed, it would be very rare to naturally find a fruit fly with an appendage growing out of
its eye raiding that decomposing banana peel in your trash!
In sum, HSP90 inhibition may reveal phenotypic diversity, but this diversity generates
evolutionary “dead ends” in an uncontrolled setting. Something similar may be happening in the
case of cancers that undergo HSP90 inhibition. Therefore, targeting HSP90 may limit the
evolution of cancers in two ways. First, by abrogating potentiation of the cancer hallmarks that
ultimately manifests in ITH. Second, by discharging cryptic variation stored in HSP90’s
capacitor function, effectively revealing evolutionary “dead ends” that are incompatible with
long-term tumor maintenance.
HSP90 Inhibitors
Targeting HSP90 with small molecule inhibitors to treat cancer has been the center of
considerable debate for almost 50 years. The first HSP90 inhibitors discovered were
geldanamycin and radicicol, two naturally occurring compounds that demonstrated anti-cancer
activity in vitro. It was soon observed that they destroyed cancer by destabilizing the interaction
between HSP90 and its clients that are also major oncogenes (Blagosklonny, Toretsky, Bohen, &
Neckers, 1996; Grenert et al., 1997; Whitesell, Mimnaugh, De Costa, Myers, & Neckers, 1994).
For example, oncogenes like v-SRC and the dominant negative form of p53, major drivers of
carcinogenesis, rely on HSP90 to maintain oncogenic stability (Walerych et al., 2004; C. Wang
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& Chen, 2003; Xu & Lindquist, 1993). If oncogenes lose interaction with HSP90, they are
targeted for degradation by the proteasome, thus limiting their role in orchestrating neoplastic
behavior. Moreover, the unusual conformation ATP adopts in the nucleotide-binding pocket of
HSP90 is also achieved by geldanamycin and radicicol, making these compounds very selective
in targeting HSP90 function. This is unlike other cancer drugs that target the ATP binding pocket
of kinases, which share significant homology in the ATP binding pocket with other kinases,
leading to off target effects.
These observations generated a flurry of research interest in HSP90 inhibitors to treat
cancer. It also garnered a fair amount of skepticism, and for good reason. Since HSP90 is
important in maintaining viability in normal cells, many believed that HSP90 inhibition would
lead to overwhelming adverse effects, rendering them inappropriate for clinical application. At
first, skeptics appeared to be correct as both geldanamycin and radicicol failed in clinical trials
due to toxic effects and poor solubility. This propelled research to improve the solubility profile
and pharmacodynamics of HSP90 inhibitors. Further research would reveal that HSP90
inhibitors have the highest affinity for tissues that have HSP90 in its “activated” form compared
to tissues with HSP90 in a latent state (Kamal et al., 2003). It appears that cancer cells have
much of its HSP90 in an active complex (Kamal et al., 2003), likely because it is busy
maintaining mutated gene products of the cancer hallmarks. This makes HSP90 inhibitors both
specific to their target through the unique GHKL binding site and specific to neoplastic tissue, a
highly coveted property of any cancer therapy. Further studies have shown that certain HSP90
inhibitors can accumulate in neoplastic tissue relative to normal tissues (Eccles et al., 2008;
Jensen et al., 2008), suggesting that HSP90 inhibitors could still be effective against cancers if
given at low doses in the right frequency.
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Research efforts and advances in medicinal chemistry have led to the development of
over a dozen different HSP90 inhibitors to date. Improvements in the solubility profiles of these
drugs have permitted many of them to progress through various phases of the clinical trial
process. HSP90 inhibitors like 17-AAG, 17-DMAG, and AUY922 have all progressed past
phase I trials; another HSP90 inhibitor, ganetespib (STA-9090), made it as far as phase III.
None have been approved, but clinical trials are still active or recruiting for multiple cancers.
What we have learned from clinical trials is that HSP90 inhibitors can deliver a specific
cytotoxic effect to cancer cells, and that the best responses are achieved when HSP90 inhibitors
are used in combination with other therapies (Bendell et al., 2015; Johnson et al., 2015; Kong et
al., 2016) (Johnson et al., 2015; Modi et al., 2011).
Despite improvements in the pharmacology of HSP90 inhibitors and some measurable
success in clinical trials, adverse effects and inconsistent tumor responses continue to hamstring
their progression to an approved therapy for cancer. Concerns regarding parallel induction of the
cancer’s survival response, impairment of antitumor immune mechanisms, cardiac arrhythmias,
and hepatotoxicity have emerged from clinical trials (Whitesell & Lindquist, 2005).
These trepidations may be due to the nature of the clinical trial process for cancer
chemotherapies. When a chemotherapy enters phase I clinical trials, a small group of patients are
enrolled, and the drug’s efficacy is evaluated by titrating to the maximum tolerated dose (MTD)
a patient can physiologically withstand and weighing the costs of adverse effects to the benefits
of tumor response to therapy. If a proper balance can be achieved, the chemotherapy under
investigation moves on to the next phase of the clinical trial. In the subsequent phases, the
chemotherapy will be compared to current gold standard treatments and the cohort sizes will
grow considerably, but the dose administered will continue to be given proximal to the MTD.
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What is interesting in terms of HSP90 inhibitors is that a fair number of them pass through phase
I, indicating a tolerable level can be achieved; but, they never get approved as a single agent for
cancer therapy due to inconsistent tumor responses relative to the gold standard treatments. The
source of inconsistency may be derived from the high doses demanded by the clinical trial
process, causing global cellular stress and inadvertent induction of the heat shock response. As
previously mentioned, the heat shock response is an adaptive mechanism, and its unintended
activation hands the cancer a tool to promote evolution and survival, rather than limit it. Also,
administering high doses of HSP90 inhibitors does not maximize the increased affinity HSP90
inhibitors have for neoplastic tissue.
If HSP90 inhibitors are specific to their target (Kamal et al., 2003) and can accumulate
within neoplastic tissue in vivo (Eccles et al., 2008; Jensen et al., 2008), low dose administration
at strategic frequencies could be a clinically viable approach to remove issues associated with
inadvertent induction of the heat shock response. Furthermore, the ability for HSP90 inhibitors to
shut down multiple cancer hallmarks simultaneously may dampen the formation of excessive
ITH, which in turn slows the clock on tumor evolution and disease progression. This may place
HSP90 inhibitors as a unique chemotherapy that can be used specifically to confront drug
resistance and metastasis in cancer. This is already starting to be revealed in studies showing
HSP90 inhibition to be useful in abrogating development of resistance to certain chemotherapies
(Jacobson et al., 2016; Nagaraju et al., 2019; Whitesell et al., 2014) and deconstructing
molecular pathways involved in epithelial to mesenchymal transition (EMT), migration and
metastasis in vitro, and, in animal xenografts of different human cancer cell lines (Chong et al.,
2019; Nagaraju et al., 2015).
Furthermore, evidence from clinical trials indicates that HSP90 inhibitors can be safely
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paired with conventional therapies (Bendell et al., 2015; Eroglu et al., 2018; Johnson et al.,
2015). Since HSP90 inhibitors can attenuate metastasis and drug resistance, it suggests that they
may be especially useful to pair with anti-cancer agents that are very potent early in the treatment
process, but are known to promote evolution of drug resistance and metastasis later, like
paclitaxel (Datta et al., 2017) (Karagiannis et al., 2017; Volk-Draper et al., 2014).
In the following chapters, we examine the clinically relevant HSP90 inhibitor, AUY922,
in its ability to curtail both metastatic and drug resistant phenotypes in cancer. We investigate
these processes in the context of non-small cell lung cancer (NSCLC), which is often drug
resistant and metastatic at the time of diagnosis or during the treatment process (Gabor et al.,
2004; Popper, 2016; Shanker, Willcutts, Roth, & Ramesh, 2010; Sosa Iglesias, Giuranno,
Dubois, Theys, & Vooijs, 2018). Our results indicate that equivalent doses of AUY922 below
those that are currently recommended in clinical trials can restrict the acquisition of drug
resistant and metastatic phenotypes in vitro. We then discuss repurposing small molecule HSP90
inhibitors as the first form of therapy designed to curb tumor evolution and disease progression,
which may be used alongside conventional therapies to generate sustained tumor remission.
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Chapter 2: Low Dose HSP90 Inhibition with AUY922 Blunts Rapid Evolution of
Metastatic and Drug Resistant Phenotypes Induced by TGF-β and Paclitaxel in A549 cells
Abstract
Despite advances in cancer treatment, metastasis and drug resistance continue to contribute to
treatment failure. Since these are features that often occur toward the late stages in the disease
after withstanding numerous selective pressures, they may rely on a shared adaptive mechanism
in order to persist. The heat shock response is one of the most well conserved adaptive responses
to cellular stress found in nature. A major player in the heat shock response is HSP90, and some
studies suggest it can facilitate the evolution of drug resistance and metastasis in cancer. Nonsmall cell lung cancers (NSCLCs) are strongly associated with metastasis and drug resistance
either at the time of diagnosis or early in the treatment process. We explored the role of HSP90
in the evolution of metastatic and drug resistant features in NSCLC by treating A549 cells with
AUY922, a clinically relevant HSP90 inhibitor, and inducing metastatic and drug resistant
phenotypes via TGF-β and paclitaxel, respectively. We used flow cytometry to measure changes
in E-Cadherin, a marker for epithelial to mesenchymal transition (EMT) and two ABC
transporters associated with drug resistant lung cancers. We found that metastatic and efflux
dependent drug resistant features negatively correlated with AUY922 treatment. We followed
our results with functional assays relevant to metastasis and ABC transporters to confirm our
results. Together our data indicates that HSP90 inhibition with AUY922 can limit the acquisition
of metastatic and drug resistant phenotypes in A549 cells at equivalent, clinically appropriate
doses.
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Background
Lung cancer is the most commonly diagnosed cancer and leading cause of cancer
mortality worldwide regardless of sex (Bray et al., 2018). 85% of lung cancers are non-small cell
lung cancers (NSCLC) (Herbst, Morgensztern, & Boshoff, 2018), with metastasis and
chemotherapeutic resistance common features of these cancers either at the time of diagnosis or
manifesting during the treatment process (Gabor et al., 2004; Popper, 2016; Shanker et al., 2010;
Sosa Iglesias et al., 2018). Therefore, discovering ways to mitigate metastasis and
chemotherapeutic resistance in NSCLCs will be beneficial to a substantial number of cancer
patients.
Metastasis is the spread of cancer cells from the primary tumor site to distant organs in
the body where they grow and disrupt normal organ function (Fidler & Kripke, 2015). The stepwise process by which carcinomas undergo the complex changes in cell signaling and gene
expression required to complete metastasis is referred to as epithelial-mesenchymal transition
(EMT) (Kalluri & Weinberg, 2009). The initial stages of EMT in carcinomas begin with loss of
cell-cell junctions. A major protein involved in maintaining cell-cell junctions that is lost during
EMT is E-cadherin (Onder et al., 2008). Loss of E-cadherin facilitates dissolution of cell-cell
junctions, permitting cancer cells to migrate from their primary site as they undergo further
changes to invade local vasculature to travel to distant organs in the body. Numerous studies in
human tumor samples have demonstrated that reduced E-cadherin expression is associated with
dedifferentiation and lymphogeneous spread (Cheng, Nagabhushan, Pretlow, Amini, & Pretlow,
1996; Dorudi, Sheffield, Poulsom, Northover, & Hart, 1993; Oka et al., 1992; Schipper et al.,
1991; Siitonen et al., 1996), including NSCLCs (Lee, Wu, Chen, & Chang, 2000; Lim, Jang,
Kim, & Park, 2000; Sulzer, Leers, van Noord, Bollen, & Theunissen, 1998). This makes E-
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cadherin a reliable and clinically relevant marker for in vitro study of metastasis in NSCLC cell
lines.
Chemotherapeutic resistance can manifest as a result of cell cycle alterations,
insensitivity to apoptosis, altered drug metabolism, increased DNA damage repair, and increased
drug efflux (Szakacs, Paterson, Ludwig, Booth-Genthe, & Gottesman, 2006). Increased drug
efflux is a common mechanism cancer cells use to protect themselves from chemotherapeutic
damage and is mediated by a family of transmembrane transporters known as ATP-binding
cassette (ABC) transporters (Fletcher, Williams, Henderson, Norris, & Haber, 2016). There are
48 known ABC transporters, and three, ABCB1, ABCC1, and ABCG2, are most commonly
found to drive efflux dependent drug resistance in human cancers (Sharom, 2008). This is
presumably because these three transporters have considerable chemotherapeutic substrate
overlap (Sharom, 2008). Two of these ABC transporters, ABCB1 and ABCC1, are commonly
overexpressed in human NSCLC tumors (Nooter et al., 1996; Sugawara et al., 1995; Wright et
al., 1998), and can play major roles in conferring multidrug resistance in NSCLCs (Berger et al.,
2005; Oshika et al., 1998; Ota et al., 1995; Volm, Mattern, & Samsel, 1991). Despite these
studies, there is some controversy as to whether ABC transporters play a significant role in drug
resistant cancers, as studies employing ABC transporter inhibitors during cancer treatment failed
to show clinical benefit (Binkhathlan & Lavasanifar, 2013). Recently, however, some experts in
the field of ABC transporters are calling for a reevaluation of ABC transporters in cancer by
pointing out inconsistencies and pitfalls in previous studies that dismissed the role of ABC
transporters in multi drug resistant cancers (Robey et al., 2018). In any case, since these
molecular pumps physically interact with common chemotherapies and can alter the
pharmacokinetics and bioavailability of other drugs, their study should not be totally ignored.
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It is understood that metastatic and drug resistant cancer cells within a tumor emerge as a
consequence of the complex dynamics of tumor evolution (Foo & Michor, 2014; Gatenby &
Brown, 2018; Turajlic & Swanton, 2016). Given the selective pressures of chemotherapy and the
harsh tumor microenvironment to overcome, there may be a common adaptive mechanism that
metastatic and drug resistant cancer cells share in order to persist in these stressful conditions
and contribute to disease progression. An adaptive response to stress that is fundamental to all
organisms is the heat shock response (Schlesinger, 1990). HSP90 is a major player in the heat
shock response known to influence numerous essential cell processes. Previous studies have
shown HSP90 to facilitate evolution of novel phenotypes (Jarosz & Lindquist, 2010; Queitsch et
al., 2002; Rohner et al., 2013; Sollars et al., 2003), including drug resistant phenotypes (Cowen
& Lindquist, 2005; Vincent, Lancaster, Scherz-Shouval, Whitesell, & Lindquist, 2013; Whitesell
et al., 2014). HSP90 also enables the metastatic cascade, as pointed out in an exhaustive review
(Tsutsumi, Beebe, & Neckers, 2009). Clinical evidence supports this hypothesis, as HSP90
overexpression in gastric and breast cancers correlates with high tumor grade, depth of invasion,
and lymph node involvement (Pick et al., 2007; J. Wang et al., 2013), all indicators of strong
induction of the metastatic cascade. Furthermore, increased HSP90 expression in various human
cancers correlates with a poor prognosis (Flandrin et al., 2008; Pick et al., 2007; Thomas et al.,
2005; J. Wang et al., 2013; Zagouri, Bournakis, Koutsoukos, & Papadimitriou, 2012).
Several lines of recent evidence indicate that pharmacological HSP90 inhibition can limit
molecular pathways involved in EMT, migration and metastasis in vitro and in animal xenografts
of different cancer cell lines (Chong et al., 2019; Nagaraju et al., 2015). Whether other clinically
relevant HSP90 inhibitors can limit these processes in NSCLC cell lines has not been
documented. Furthermore, certain HSP90 inhibitors have demonstrated synergistic anticancer
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effects with conventional cytotoxic chemotherapies such as paclitaxel (Munster, Basso, Solit,
Norton, & Rosen, 2001; Solit, Basso, Olshen, Scher, & Rosen, 2003) and doxorubicin (Munster
et al., 2001). While the results of these studies attributed the synergistic effect to mechanisms
related to cell signaling, paclitaxel is a known substrate for ABCB1 and doxorubicin is a known
substrate for both ABCB1 and ABCC1 (Cole et al., 1992; Sharom, 2008). This leaves open the
possibility that perhaps some of the synergistic effects of HSP90 inhibition may be due to
intracellular accumulation of paclitaxel and doxorubicin as a result of altered ABC transporter
expression. The theoretical basis for this partly exists due to the fact that ABCC1 is a verified
HSP90 client (Picard, 2019), and HSP90 inhibition classically results in degradation of client
proteins. However, no relationship between HSP90 inhibition and reduced expression of ABC
transporters has been demonstrated in the context of multidrug resistant cancer to date.
In the present study we ask whether treatment with the clinically relevant HSP90
inhibitor, AUY922, given at the same dose and exposure time, could limit rapid acquisition of
metastatic traits and ABC transporter driven drug resistance in A549 cells, a common NSCLC
cell line. AUY922 is unique among HSP90 inhibitors as it is readily soluble in ethanol and can
inhibit both the inducible (HSP90α) and constitutive (HSP90β) isoforms of HSP90 at low
nanomolar concentrations (Eccles et al., 2008; Garon et al., 2013). We were guided by the work
of others who used relatively low doses of HSP90 inhibition to abrogate emergence of drug
resistant phenotypes in MCF-7 breast cancer cells (Whitesell et al., 2014). If successful, our
work would further strengthen the case for other clinically relevant HSP90 inhibitors, and
AUY922 in particular, to be deployed in the clinic at low doses as an adjunct to prevent
acquisition of drug resistance and metastasis that can be associated with some cytotoxic
chemotherapies (Karagiannis et al., 2017; Volk-Draper et al., 2014). Furthermore, successfully

27

utilizing smaller doses of chemotherapy can be expected to improve the quality of life for cancer
patients undergoing chemotherapy.
Materials and Methods
CELL CULTURE
A549 cells were purchased from the European Collection of Authenticated Cell Cultures
(ECACC)(Account #: 86012804; Lot: 165012) and cultured in RPMI-1640 media supplemented
with 10% FBS and 25mM HEPES buffer. All experiments were performed between passages 5
and 20 from the original purchased vial.
CELL VIABILITY ASSAY (XTT)
The viability of A549 cells under AUY922 and paclitaxel treatment was assessed in
parallel using the XTT assay (Biotinium; catalog #: 30007) per manufacturer recommended
protocol. Plates were read on Spectramaxi3x® microplate reader at wavelength 450nM. Each
experiment was performed three times.
WESTERN BLOT
A549 cells were seeded in six-well plates at 4.0x105 cells/well and allowed to attach
overnight. The next day, medium was aspirated and replaced with 1.0mL fresh growth medium
and treated with indicated drug. After 6 hours, medium was aspirated and the cells were
harvested, quantified, and transferred to nitrocellulose membranes as described(Mahmood &
Yang, 2012). Primary antibodies were used at a dilution of 1:1500 mouse anti-HSP70
(Enzo,ADI-SPA-810-D, clone: C92F-3A-5) and 1:10000 mouse anti-GAPDH (cat#:12345).
Species-specific europium-conjugated secondary antibody (ScanLater goat anti mouse; part#:
R7562; Molecular Devices®) was used. Afterward, membranes were washed with TBS-T and
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analyzed via Spectramaxi3x® western blot cartridge (Molecular Devices®). Two independent
experiments were performed in triplicate (n=6).
FOUR DAY EMT INDUCTION IMMUNOPHENOTYPING
A549 cells were seeded into six-well plates (50,000 cells/well) and allowed to attach
overnight. Medium was aspirated and replaced with 2.0mL fresh growth medium and treated
with drug for 48 hours. After, medium was aspirated from each well and replaced with 2.0mL of
fresh growth medium. One plate from each treatment group was treated with 10ng/mL TGF-β
(Peproptech, Cat#:100-21), while the others remained in untreated medium for an additional 48
hours. Afterward, cells were detached with trypsin for 15 minutes, placed into flow tubes,
washed, stained for viability (Zombie-NIR, 77184, Biolegend), counted via typan blue,
normalized to cell numbers, and blocked as previously described (Lawag et al., 2017). Samples
were stained with the following fluorescently conjugated antibodies: Alexafluor®647 antihuman E-Cadherin (BD Biosciences, 56371, clone: 67A4), Alexafluor®488 anti-human ABCC1
(BioLegend, 370306, clone: QCRL-3), and Brilliant Violet ®421 ABCB1 (BD Biosciences,
566015, clone: UIC2) per sample for 30 minutes on ice protected from light. Samples were
washed twice with 2.0mL cold FACS buffer, centrifuging at 300g for 5 minutes between washes.
After second wash, samples were decanted and gently resuspended in residual buffer with a pipet
tip to generate a homogenous single cell suspension and analyzed via flow cytometry. Three
independent experiments were performed in triplicate for each treatment group (n=9).
WOUND HEALING ASSAY
A549 cells were seeded into six well plates (50,000 cells/well) and allowed to attach
overnight. Cultures were treated with drug for 48 hours. After, cells were detached with trypsin,
collected in separate 50mL tubes and spun at 300g for 5 minutes. Supernatant was decanted, and
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pellets were resuspended in 1.0mL fresh growth medium. 3.0x105 cells were collected from each
tube and resuspended in 400μL of fresh growth medium. We empirically determined that this
cell concentration would yield a confluent monolayer when seeded into 20μL drops and allowed
to attach overnight (15,000 cells/drop). Three 20μL drops were seeded into the top row of three
six well plates, one plate per treatment group (9 drops per treatment group in total) and allowed
to attach overnight. Cells were then scratched with a 200μL pipet tip and 1.0mL of fresh growth
medium was added to each well. Pictures and measurements were taken at time 0 hours and time
18 hours over the middle of the colonies by drawing a single straight line through the nuclei of
cells on the left side of the migration front and dropping three perpendicular lines across the
viewing field (one at the top, one through the middle and one at the bottom) to the migration
front on the right. Migration index was calculated by dividing average starting gap width by the
average gap width at 18 hours. Two independent experiments were performed (n=18 for each
treatment group).
TRANS-EPITHELIAL ELECTRIC RESISTANCE (TER) ASSAY
A549 cells were seeded into 6 transwells (10,000 cells/well) and allowed to grow for 72
hours. At this time point, fresh medium was given, and three wells were treated with 20 nM of
AUY922. TER measurements were taken at 24 hours within 5 minutes of removing from the
incubator so as to eliminate the influence of temperature on our measurements. Final values were
obtained by subtracting the resistance of the bathing solution and an empty support. Results are
expressed as ohms per square centimeter (Ω·cm2). To compare effects obtained in different
monolayers on different days, we normalized data as described (Larre et al., 2010). Two
independent experiments were performed in triplicate (n=6).
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EIGHT DAY MDR INDUCTION IMMUNOPHENOTYPING
In these experiments we utilized what we learned from the up regulation of ABC
transporters under paclitaxel treatment during the four day EMT induction experiments. We
treated with AUY922 during the first 48 hours of the experiment as before, but instead of
inducing changes in E-cadherin with TGF-β, we induced changes in ABC transporters with
paclitaxel. We extended the experimental timeline from four days to eight days to provide cells
pretreated with AUY922 an additional 2 days to expand in untreated media after their initial
treatment during the first 48 hours of the experiment (expansion in untreated medium during
days 2-4) and after induction of ABC transporters with paclitaxel during days 4-6 (expansion in
untreated medium during days 6-8). A549 cells were collected from stock flask and thirty 20μL
drops (8,000 cells/drop, 2.4x105 cells/petri dish) were seeded into 100mm petri dishes and
allowed to attach overnight. This method of seeding provided reproducible circular colonies over
the course of the experiment that captures some of the three dimensional dynamics that exists
within a tumor, with cells at the periphery having fewer cell neighbors and more access to space
and nutrients compared to cells in the middle of the colony (a “pseudo-slice” of the tumor). The
following day, 7.0 mL of fresh growth medium was added to each petri dish and cells were
treated with AUY922. After 48 hours, treated medium was aspirated and replaced with 8.0mL of
fresh untreated growth medium. After an additional 2 days, medium was aspirated and replaced
with 10.0mL of fresh growth medium. At this time point some petri dishes were treated with
10nM of paclitaxel (MDR induction), while the others remained untreated (no MDR induction).
Petri dishes were allowed to grow for an additional 2 days. On day 6, medium was aspirated
from each petri dish and replaced with 10.0mL of fresh untreated growth medium and allowed to
grow for an additional 2 days. On day 8, cells were harvested. The entire growth medium from
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each petri dish was placed into separate 50mL tubes and petri dishes were washed once with
5.0mL PBS, which was subsequently aspirated. Cells were detached with trypsin/4mM EDTA
for 20 minutes at 37oC, and placed into corresponding 50mL tubes with previously collected
growth medium. Cells were washed, stained for viability, counted, normalized to cell numbers,
and blocked as previously described (Lawag et al., 2017). Each sample was stained with
fluorescently conjugated antibodies: Alexafluor®488 anti-human ABCC1 (BioLegend, 370306,
clone:QCRL-3), and Brilliant Violet ®421 ABCB1 (BD Biosciences, 566015, clone:UIC2) per
sample for 30 minutes on ice protected from light. Samples were washed twice with 2.0mL cold
FACS buffer, decanted and centrifuged at 300g for 5 minutes between washes. After second
wash, samples were decanted and pellets gently resuspended in residual cold FACS buffer with a
pipet tip to generate a homogenous single cell suspension and analyzed via flow cytometry. At
least two independent experiments were performed with at least two biological replicates per
treatment (no MDR induction n=5, MDR induction n=8).
DOXORUBICIN EFFLUX ASSAY
A549 cells were seeded in thirty 20μL drops in 100mm petri dishes, and cultured as
described in the eight-day experiment for MDR induction. On day eight, cells were harvested
and 2.5x105 cells were placed into flow tubes, washed with growth medium and centrifuged at
300g for 5 minutes. Supernatant was decanted, and pellets were gently resuspended in 500μL of
warm growth medium treated with 10μM of doxorubicin. Cells were incubated at 37 oC for 30
minutes to load with doxorubicin. Samples were washed in growth medium and centrifuged at
300g for 5 minutes. Supernatant was decanted, and pellets resuspended in 1.0mL of growth
medium. Samples were incubated at 37oC with agitation for 2 hours. Afterward, samples were
washed with 2.0mL of room temperature PBS followed by centrifugation at 300g for 5 minutes.
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Supernatant was decanted, and pellets were resuspended in 200μL of Zombie-NIR viability
reagent, which was applied per manufacturer’s instructions. After the final wash and decant, cells
were gently resuspended in residual cold FACS buffer with a pipet tip to generate a homogenous
single cells suspension and analyzed via flow cytometry. Three independent experiments were
performed in at least duplicate (n=8).
FOUR, SIX AND EIGHT DAY CULTURE GROWTH
A549 cells were collected from stock flask, seeded in 20μL drops in 100mm petri dishes,
and cultured as described in the eight-day experiment for both non-MDR induction and MDR
induction groups. On day four and six, cells were washed and detached as described in the eightday experiment. Instead of resuspending in 1.0mL of zombie reagent, cells were resuspended in
1.0mL of fresh growth medium, and a 10μL aliquot was taken from each sample to count via
hemacytomter and 0.4% typan blue staining. For samples without MDR induction with
paclitaxel, a single experiment was performed in triplicate for day four and day six (n=3 for each
day). For samples with MDR induction with paclitaxel, two independent experiments in triplicate
were performed on days four and six (n=6 for each day). Day eight counts were a combination of
counts gathered on day eight from MDR induction immunophenotyping and doxorubicin efflux
studies.
FLOW CYTOMETRIC ANALYSIS
All flow cytometric analysis were performed via Novocyte ® 3000 flow cytometer
(ACEA Biosciences, Inc., San Diego, California). 50,000 single cell events were analyzed. All
data analysis was performed using NovoExpress Software version 1.3.0 (ACEA Biosciences,
Inc., San Diego, California). For all antibodies, we used fluorescence minus one (FMO) and
corresponding isotype controls to determine positive staining background. All data analysis was
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performed using NovoExpress Software version 1.3.0 (ACEA Biosciences, Inc., San Diego,
California).
STATISTICAL ANALYSIS
All statistical analysis was performed using Prism8.0a software (GraphPad Software Inc.,
San Diego, California). Appropriate statistical tests were performed with corresponding
significance values indicate in figure legends. For the E-cadherin flow cytometry studies and
wound-healing assay, analysis was performed using one-way ANOVA with Tukey’s test for
multiple comparisons. For trans-epithelial resistance, eight-day flow cytometry studies without
MDR induction, eight-day growth curves, and doxorubicin efflux studies, analysis was
performed using Student’s t test for unpaired data. For ABC transporter flow cytometry studies
with/without EMT and with MDR induction, analysis was performed using one-way ANOVA
with Dunnet’s test for multiple comparisons.

Results
AUY922 AND PACLITAXEL HAVE SIMILAR EFFECTS ON A549 CELL VIABILITY AFTER 48
HOURS EXPOSURE
Before investigating metastatic and drug resistant properties of A549 cells, we had to
evaluate their sensitivity to AUY922 and paclitaxel. Paclitaxel was used in many of our studies
as it is currently used in combination with other chemotherapies in NSCLC and has been
associated with development of metastasis (Karagiannis et al., 2017; Volk-Draper et al., 2014)
and ABC transporter driven drug resistance (Datta et al., 2017). Intriguingly, A549 cells
displayed almost identical viability curves to increasing doses of either drug at 48 hours of
exposure (Figure 6A). Since we were most interested in evaluating how A549 cells change in
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Figure 6. Chemosensitivy of A549 Cells to Paclitaxel and AUY922 and HSP70 Induction
(A): Chemosensitivity of A549 cells to 48 hour exposure to increasing concentrations of
Paclitaxel (blue) and AUY922 (green) ranging from 0.001-2,000nM. Viability was determined
using the XTT assay. Each dose was performed in sextet per individual experiment. Data
represents the mean ±95% CI of three independent experiments. EC50 A549 v PTX: 30.2 (95%
CI 25.0-36.8nM); EC50 A549v AUY922: 25.4 (95% CI 22.3-28.5nM) (B) Growth curves of
A549 cells after 48 hours of indicated drug followed by 48 hours of untreated medium. (C)
Induction of HSP70 expression by HSP90 inhibition with AUY922 after only six hours of
exposure. A representative blot of two independent experiments performed in triplicate is shown.
response to these drugs, not necessarily how they are killed, we wanted to refrain from using
high doses of either drug in our experiments to avoid selecting for a particular metastatic or drug
resistant phenotype in the A549 cell population. We decided we could achieve this by focusing
on doses below the EC50, which in this case would be doses less than 25nM for AUY922 and
less than 30nM for Paclitaxel (Figure 6A).
Since paclitaxel can exhibit additional growth inhibition beyond 48 hours (Figure 6B),
we decided that 10nM treatment with paclitaxel would be appropriate to further ensure we do
not select for any particular phenotype, as our planned experimental endpoints were to extend
well beyond 48 hours. We chose 20nM of AUY922 as this dose was enough to demonstrate up
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regulation of HSP70 (Figure 6C) and is below the EC50. Up regulation of HSP70 is considered
a reliable indicator of successful pharmacological HSP90 inhibition (Whitesell et al., 2014). We
used Cmax values gathered from clinical trials (Doi et al., 2014; Kong et al., 2016; SeggewissBernhardt et al., 2015; Sessa et al., 2013) to confirm that 20nM of AUY922 is well within a
clinically relevant treatment range.
AUY922 PROMOTES E-CADHERIN SURFACE EXPRESSION IN A549 CELLS, WHICH REMAINS
DURABLE AFTER EMT INDUCTION WITH TGF-Β
Induction of EMT is a well-known method to study metastasis in vitro and is thought to
drive metastatic changes in vivo (Tsai & Yang, 2013; Zhao et al., 2016). A hallmark of EMT is
loss of E-cadherin and studies have demonstrated reduced E-cadherin expression in NSCLC
tumors derived from clinical samples correlates with poor tumor differentiation and invasion of
local structures including vasculature (Lee et al., 2000). Therefore, we reasoned that E-cadherin
would be a suitable marker to evaluate changes related to metastatic progression that would
translate to the clinic.
We exposed A549 cells to 20nM of AUY922 or 10nM of paclitaxel for 48 hours,
followed with 48 hours in untreated media, and captured phenotypic changes via flow cytometry.
Treatment with AUY922 promoted the E-cadherin positive fraction while paclitaxel reduced Ecadherin positive fraction, relative to the control (Figure 7 A, B). Additionally, there was a
significant increase in median fluorescence intensity (MFI) in AUY922 treated group cultures
relative to either paclitaxel treated cultures or control cultures, an indication that the positive
fraction had an overall increase in E-cadherin expression per cell in the positive fraction (Figure
7C).
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Figure 7. E-cadherin Immunophenotyping without EMT Induction
(A) Flow cytometric analysis of E-Cadherin expression after 48 hours of treatment followed by
48 hours in untreated medium (w/o EMT induction). (B) Quantification of the percentage of cells
positive for E-Cadherin w/o EMT induction. Data is representative of the mean ±SEM of three
independent experiments performed in triplicate (n=9). (C) Quantification of the median
fluorescence intensity of the E-cadherin positive fraction. Data is representative of the mean
±SEM of three independent experiments performed in triplicate (n=9). ****P<0.0001.
To evaluate the durability of the increase in E-cadherin expression triggered by AUY922, we
decided to follow the initial 48-hour treatment period with 48 hours in TGF-β treated media.
TGF-β is a well-known and potent inducer of EMT in A549 cells (Kasai, Allen, Mason,
Kamimura, & Zhang, 2005). While 20nM of AUY922 did not completely desensitize A549 cells
to TGF-β driven EMT in these cultures, both the percent positive fraction and the median
fluorescence were significantly higher than either the paclitaxel treated or control cultures
(Figure 8A-C). Together, this data suggests that AUY922 generates changes in A549 cells that
promote E-cadherin expression that remains durable even in the presence of strong drivers of the
metastatic cascade such as TGF-β, relative to paclitaxel treatments or control cultures.
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Figure 8. E-cadherin Immunophenotyping with EMT Induction
(A) Flow cytometric analysis of E-Cadherin expression after 48 hours of treatment followed by
48 hours EMT induction in medium supplemented with 10ng/mL of TGF-β. (B) Quantification
of the percentage of cells positive for E-Cadherin with EMT induction. Data is representative of
the mean ±SEM of three independent experiments performed in triplicate (n=9).
(C) Quantification of the median fluorescence intensity of the E-cadherin positive fraction with
EMT induction. Data is representative of the mean ±SEM of three independent experiments
performed in triplicate (n=9). **P<0.01; ****P<0.0001.
AUY922 LIMITS MOTILITY OF A549 CELLS
If E-cadherin loss is associated with increased invasion and metastasis, then it is
reasonable that the increase in E-cadherin we observed with AUY922 treatment could influence
the migratory capacity of A549 cells. To investigate this, we exposed A549 cells to 20nM of
AUY922 and 10nM of paclitaxel for 48 hours and performed a wound-healing assay as
described. As expected, AUY922 treated cells had drastically limited migration capacity
compared to paclitaxel treated or control cultures (Figure 9A, B).
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Figure 9: Effect of AUY922 Treatment on Migratory Capacity and Tight Junction
Formation in A549 Cells.
(A) After 48 hours of drug exposure, cell numbers were normalized by reseeding in 20uL drops
(15,000 cells/drop) and allowed to attach overnight. The circular colonies that formed were then
scratched with 200uL pipette tip and pictures were taken at time 0 hours (top) and 18 hours
(bottom). Two individual experiments were performed. Images are representative scratches from
an individual colony. There were 9 total colonies per experiment per treatment group (n=18). (B)
Quantification of mean migration index calculated by dividing starting gap width by the gap
width at 18 hours. (C) Change in trans-epithelial electric resistance (TER) across confluent
monolayers of A549 cells after 24 hours of 20nM AUY922 treatment. Two independent
experiments were performed in triplicate (n=6); All data is representative of the mean ±SEM of
two independent experiments performed as described**P<0.01, ****P<0.0001
AUY922 PROMOTES TIGHT JUNCTION FORMATION IN A549 CELLS
The increase in E cadherin expression under AUY922 treatment prompted us to find
additional details to identify a more definitive cause for the lack of migration in the scratch
assay. Increased E-cadherin expression may indicate the promotion of tight junctions between
cells (Mendonsa, Na, & Gumbiner, 2018). To investigate this, we plated A549 cells in transwell
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plates and measured tight junction formation via trans-epithelia resistance (TER) in each of our
previous treatment conditions. At 24 hours, there was a substantial TER increase in AUY922
treated cultures relative to control cultures (Figure 9C).
This observation helps explain the lack of migration of AUY922 treated A549 cells in the
wound healing assays. By promoting tight junction formation, the increased intensity in cell-cell
adhesion makes it less likely for the cells at the edge of the scratch to migrate into the gap. This
places AUY922 as a potential cell-cell adhesion enhancer, which has benefits in the context of
cancer metastasis as increases in cell-cell adhesion discourages cancer cells from migrating
outside the primary tumor.
AUY922 TREATMENT DOES NOT INDUCE SURFACE EXPRESSION OF ABCB1 OR ABCC1
COMPARED TO PACLITAXEL TREATMENT
During the EMT induction experiments where we exposed A549 cells to 48 hours of
AUY922 or paclitaxel and followed with 48 hours of untreated medium or TGF-β treated
medium to measure E-cadherin expression, we also probed expression of ABCB1 and ABCC1.
These two ABC transporters are also commonly known as P-glycoprotein (P-gp) and multidrug
resistance protein 1 (MRP1), respectively. In agreement with others (Synold, Dussault, &
Forman, 2001; Vesel et al., 2017), paclitaxel treatment in A549 cells promoted a slight increase
in ABCB1 positive fraction relative to the control cultures at the end of the four day period, with
enhanced ABCB1 positive fraction under induction of EMT with TGF-β in the final 48-hour
time period (Figure 10A-C). Paclitaxel treated cultures also had a similar increase in ABCC1
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Figure 10: Drug Transporter Expression in EMT Induction Experiments.
(A) ABCB1 expression without EMT induction (Top) and with EMT induction with TGF-β
(Bottom) of indicated drug treatments. (B) Quantification of the percentage of cells positive for
ABCB1 without EMT induction. Data is representative of the mean ±SEM of three independent
experiments performed in triplicate (n=9). (C) Quantification of the percentage of cells positive
for ABCB1 and EMT induction. Data is representative of the mean ±SEM of three independent
experiments performed in triplicate (n=9). (D) ABCC1 expression without EMT induction (Top)
and with EMT induction with TGF-β (Bottom) of indicated treatments. (E) Quantification of
three independent experiments performed in triplicate (n=9). (F) Quantification of percentage of
cells positive for ABCC1 with EMT induction. Data is representative of the mean ±SEM of three
independent experiments performed in triplicate (n=9). *P<0.05, ***P<0.001, ****P<0.0001.
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positive fraction relative to the control with or without TGF-β in the final 48 hours before
capture (Figure 10D-F).
In contrast, there was no increase in ABCB1 or ABCC1 relative to the control in
AUY922 treated cultures regardless of TGF-β treatment (Figure 10). While the changes in
AUY922 cultures were of little statistical significance compared to control cultures, considered
as a whole there was a general downward trend, especially in AUY922 treated cultures exposed
to TGF-β in the final 48 hours before capture (Figure 10C, F). This was interesting to us since
A549 cultures treated with AUY922 received a chemical stimulus at twice the molar dose of
paclitaxel cultures, yet remained insensitive to induction to part of the xenobiotic defense
response for which ABC transporters evolved to carry out (Dean & Annilo, 2005). With this
information, we formed a new strategy to maximize the resolution of our putative observations
of the reduced positive fraction of ABCB1 and ABCC1 under AUY922 treatment. From here
forward, loss or gain of ABCB1 and ABCC1 will be referred to as the MDR phenotype.
SINGLE TREATMENT WITH AUY922 REDUCES MDR PHENOTYPE AND DESENSITIZES A549
CELLS TO INDUCTION OF MDR PHENOTYPE VIA PACLITAXEL TREATMENT
In order to maximize the resolution of our observations of putative reduction in ABC
transporter expression with AUY922 treatment, we altered the protocol as described in the
methods. This experimental timeline mimics a scenario in which a cancer patient may receive
multiple chemotherapies in cycles on alternating days, adding a level of clinical relevance to this
experimental strategy.
Our adjustments to the experimental protocol proved to be successful. A549 cells treated
with 20nM AUY922 for 48 hours followed by fresh media for the remaining 6 days
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Figure 11: Flow Cytometric Analysis of ABC Transporters Captured at Day 8 after
Indicated Drug Treatment.
(A) (Top) ABCB1 (Bottom) ABCC1 expression in A549 cells after a single treatment with 20nM
AUY922. (B) Quantification of the percentage of cells positive for ABCB1 captured at day 8 (C)
Quantification of the percentage of cells positive for ABCC1 captured at day 8. All data is
representative of the mean ±SEM of two independent experiments performed at least in duplicate
(n=5). *P<0.05, **P<0.01.
demonstrated reduced positive fraction of the MDR phenotype (Figure 11A-C) relative to
control cultures that received fresh untreated media every 48 hours for 8 days (Figure 11A-C).
Additionally, cells pretreated with 20nM AUY922 for the first 48 hours appeared to be
insensitive to induction of the MDR phenotype with 10nM paclitaxel on days 4-6 compared to
control cultures that only received 10nM of paclitaxel on days 4-6 and showed dramatic
induction of the MDR phenotype (Figure 12A-D). The observation of reduced induction of the
MDR phenotype under AUY922 treatment appeared to be dose dependent, as pretreatment with
10nM of AUY922 also demonstrated a proportional decrease in the MDR phenotype (Figure
12A-D). It appears that just as AUY922 treatment desensitized A549 cells to acquisition of a
metastatic phenotype through TGF-β driven EMT, they also appear insensitive in attaining the
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Figure 12: Flow Cytometric Analysis of ABC Transporter Expression Captured at day 8
for Cultures Treated with 10nM Paclitaxel to Induce MDR.
(A) ABCB1 expression in A549 cells after a single treatment of AUY922 followed by MDR
induction with 10nM Paclitaxel (PTX) as described. (B) Quantification of the percentage of cells
positive for ABCB1 captured at 192 hours. (C)ABCC1 expression in A549 cells after a single
treatment of AUY922 followed by MDR induction with 10nM Paclitaxel (PTX) as described.
(D) Quantification of the percentage of cells positive for ABCC1 captured at 192 hours.
PTX=10nM Paclitaxel. Text before the slash indicates treatment conditions during the first 48
hours of the experiment. Text after the slash indicates treatment conditions from days 4 to 6. All
data is representative of the mean ±SEM of three independent experiments performed at least in
duplicate (n=8). *P<0.05, **P<0.01, ****P<0.0001
MDR phenotype. Furthermore, MDR induction with paclitaxel generated a robust double
positive ABCB1 and ABCC1 population, which was not present in cultures that did not receive
MDR induction with paclitaxel (data not shown). This was also where the greatest reduction in
the MDR phenotype as a result of AUY922 treatment appeared to occur (Figure 13). This is a
significant finding because ABCB1 and ABCC1 have considerable substrate overlap in

44

Figure 13. Flow Cytometric Analysis Captured at Day 8 of All Four Populations of A549
Cells after MDR Onduction on Day 4 with 10nM Paclitaxel (PTX)
(A) (Top) Representative flow plots demonstrating strong induction of ABCB1+ABCC1+
(double positive) population that decreases under AUY922 treatment in a dose dependent
manner. Text before the slash indicates conditions from hours 0-48, text after the slash indicates
conditions from hours 96-144. (A)(Bottom) Same view, but with colors designating the four
populations to give a sense of the heterogeneity within the cultures. (B) Quantification of the
percentage of cells in all four populations captured on day 8 according to the colors in (A). Data
is representative of the mean ±SEM of three independent experiments performed at least in
duplicate (n=8). *P<0.05, **P<0.01, ****P<0.0001
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chemotherapies commonly used to treat lung cancer (Sharom, 2008), and experimental evidence
suggests expression of multiple ABC transporters are required for cancers to achieve multidrug
resistance (Bartholomae et al., 2016; Marzac et al., 2011) (Robey et al., 2018). This means that
HSP90 inhibition with AUY922 has the potential to limit the formation of lung cancer cells that
can generate the greatest efflux of chemotherapies across their cell membrane.
LOSS OF MDR PHENOTYPE FROM AUY922 TREATMENT HAS A FUNCTIONAL CONSEQUENCE
THAT IMPACTS A549 CELL SURVIVAL
Our results indicating that treatment with AUY922 desensitizes A549 cells to induction
of the MDR phenotype with paclitaxel suggest that these cells are more sensitive to cell death via
paclitaxel treatment than controls treated with paclitaxel alone on day 4. However, given that
ABC transporters are only one of several methods in which cancer cells can generate multi drug
resistance, and the wide range of signaling pathways that may be altered by HSP90 inhibition, it
is possible that we could be reducing one mechanism of multidrug resistance with AUY922
while reinforcing another. To investigate if AUY922 altered the viability of A549 cells over the
8-day period, we began tracking the culture growth at important time points in the experiment, in
particular days 4, 6 and 8. A549 cells that received fresh medium every 2 days for 8 days showed
classical unimpeded exponential growth, while A549 cells that received 20nM of AUY922 for
the first two days followed by fresh medium every two days for the next 6 days showed a
significant slowing of culture growth at each time point throughout the experiment, but an
overall positive slope to the growth curve (Figure 14A).
In the treatment groups that received 10nM of paclitaxel on day 4 followed by fresh
medium on day 6, more complex changes in culture growth were observed. A549 cells that
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Figure 14: Growth Curve during 8 Day ABC Transporter Experiments and Doxorubicin
Efflux Assay
(A) Growth curve of A549 cultures during the 8 day experiment after a single 48 hour 20nM
treatment of AUY922. (B) Growth curve of A549 cultures exposed to 10nM of paclitaxel to
induce MDR as described after 48 hour pretreatment with indicated doses of AUY922 (n=6). (C)
Comparison of viable cells at hours 144 and hours 192 in cultures pretreated with 20nM
AUY922 followed by MDR induction, indicating significant difference in viability. (D)
Doxorubicin efflux assay representative flow cytometry histogram median fluorescence intensity
of the total population of A549 cultures treated with 10nM of paclitaxel on day 4 (blue) and
A549 cells pretreated with 20nM of AUY922 before receiving 10nM of paclitaxel on day 4
(green). Black curve represents negative control. (E) Doxorubicin efflux assay quantification of
the median fluorescence intensity of doxorubicin accumulation of the total cell population treated
as indicated (n=8). In (B) and (C), text before the slash indicates conditions from hours 0-48, text
after the slash indicates conditions from hours 96-144. All data is representative of the mean
±SEM of three independent experiments performed at least in duplicate. *P<0.05, **P<0.01,
***P<0.001, ***P<0.001, ****P<0.0001
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remained untreated until they received 10nM of paclitaxel on day 4 showed a slowing of growth
from days 4 to 6, but on days 6 to 8 demonstrated accelerated growth (Figure 14B black line).
In contrast, A549 cells treated with 10nM and 20nM AUY922 showed a similar slowing of
culture growth from days 4 to 6, but a dose dependent decrease in the slope of the growth curve
from days 6 to 8 (Figure 14B orange and green lines). In the case of 20nM of AUY922
treatment during the first two days, there was a negative slope to the growth curve from days 6-8.
These results may be explained by our previous findings of reduced MDR phenotype in
A549 cells pretreated with AUY922 captured on day 8 via flow cytometry (Figures 5 and 6).
When A549 cells treated with AUY922 throughout the first 2 days of the experiment are unable
to access the MDR phenotype during paclitaxel treatment during days 4-6, they cannot efflux
paclitaxel when they receive fresh medium on days 6-8, thus promoting A549 cell death and a
decrease in the slope of the growth curve during this time (Figure 14B, C).
This analysis only explains the role of ABCB1 in paclitaxel efflux, since ABCC1
effluxes paclitaxel poorly (Borst, Evers, Kool, & Wijnholds, 2000). To account for both ABCB1
and ABCC1 in the MDR phenotype and the results of the growth curve in cultures that received
paclitaxel on day four, we decided to perform an efflux assay using doxorubicin as a fluorescent
substrate. Doxorubicin is a substrate for both ABCB1 and ABCC1 (Sharom, 2008) and has
intrinsic fluorescent properties that make it ideal to study drug efflux via flow cytometry. This
method in using doxorubicin to study efflux activity of ABC transporters has been used by other
investigators (Chen et al., 2015; Punia, Raina, Agarwal, & Singh, 2017) and we developed our
assay in accordance with these studies. We performed the eight-day experiment just as before,
but instead of immunophenotyping for ABCB1and ABCC1, we loaded the cells with

48

doxorubicin and provided a washout period to allow doxorubicin efflux, before analysis via flow
cytometry. If our observation of the reduced MDR phenotype in AUY922 treated A549 cells is
valid, these cultures should accumulate doxorubicin to a greater extent than A549 cells that
received paclitaxel alone. Indeed, this was our result (Figure 14D), with significant change
occurring in A549 cells that received 20nM of AUY922 (Figure 14E). Our efflux assay did not
indicate a significant change between cultures that only received MDR induction with paclitaxel
on day four compared to cultures treated with 10nM AUY922 before MDR induction with
paclitaxel, even though there was a significant decrease in the MDR phenotype in these cells.
This may be due to a threshold effect, where accumulation of drug in the A549 cell population
does not occur unless transporter activity is reduced to a threshold level.
Together, the growth curve analysis and the efflux assay serves to support the results of
the decreased MDR phenotype in AUY922 treated cells captured via flow cytometry during the
eight-day experiment. The growth curve analysis also shows that we are not engaging other drug
resistance mechanisms that are sufficient to restore cell survival as a product of AUY922
treatment. Furthermore, the resultant reduction in ABCB1 and ABCC1 positive fraction in the
culture is sufficient to generate a functional consequence that leads to intracellular accumulation
of chemotherapy, promoting cell death.
Discussion
Previous studies have implicated HSP90 in facilitating cellular mechanisms that drive
metastasis and drug resistance in several cancer types, and that pharmacological HSP90
inhibition can deconstruct these mechanisms (Chong et al., 2019; Nagaraju et al., 2015;
Whitesell et al., 2014). However, these studies only evaluated drug resistance and metastasis
separately. Here we demonstrate that HSP90 inhibition with AUY922 can limit both metastatic
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and drug resistant features in A549 NSCLC cells at the same clinically relevant dose. Moreover,
these changes can be maintained even in the presence of strong inducers for metastatic and drug
resistant phenotypes over a relatively prolonged time frame.
Our findings support the work of others demonstrating HSP90 inhibition abrogates EMT
in other cancers (Chong et al., 2019; Nagaraju et al., 2015). However, this is the first
documentation of these observations in A549 NSCLC cells with AUY922. The increased Ecadherin expression in our flow cytometry studies combined with our wound healing assays and
TER measurements indicates that AUY922 treatment enhances cell-cell adhesion. This is
pertinent to NSCLC, which is often locally advanced at the time of diagnosis (Gabor et al., 2004;
Popper, 2016). Immediate intervention with low dose AUY922 may be a useful treatment
strategy in preventing further progression of the metastatic cascade in these cancers.
By carefully studying the flow cytometry plots during the four day EMT induction
experiments, we also have evidence that HS90 inhibition with AUY922 simplifies the
heterogeneity in the cultures relative to untreated or paclitaxel treated cultures in terms of Ecadherin positive and E-cadherin negative cells. In cultures that did not receive EMT induction,
after a single treatment with AUY922, the culture shifts to mostly E-cadherin positive, whereas
the paclitaxel cultures and the control have more balanced percentages of E-cadherin positive
and E-cadherin negative populations. Under paclitaxel treatment, the heterogeneity is even more
dramatic as the flow plots reveal what appear to be two distinct populations beginning to diverge
from one another in the culture, whereas the control culture maintains a robust positive and
negative population that is grouped close together. During EMT induction with TGF- β,
AUY922 cultures do not transition as far as the two cultures that retained balanced positive and
negative E-cadherin populations. Even on this relatively short time scale, these findings support
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the hypothesis that HSP90 inhibition can reduce ITH such that it is less prone to acquiring
metastatic properties.
To the best of our knowledge, we are the first to document the relationship between
HSP90 inhibition with AUY922 in A549 cells and reduced cell surface expression of ABCB1
and ABCC1 with any HSP90 inhibitor in any cancer cell line. A single treatment with AUY922
is enough to maintain a significant reduction in both ABCB1 and ABCC1 for up to 8 days.
Moreover, pretreatment with AUY922 suppressed cell surface expression of ABCB1 and
ABCC1, even when stimulated to induce ABC transporter expression with paclitaxel. We were
able to demonstrate a functional consequence of these findings by tracking cell growth over the
eight-day experimental timeline and through efflux studies using doxorubicin, which is a
substrate for both ABCB1 and ABCC1, as a fluorescent drug accumulation marker. Our findings
and experimental design are clinically relevant since both ABCB1 and ABCC1 are thought to
play a significant role in drug resistant NSCLCs (Berger et al., 2005; Oshika et al., 1998; Ota et
al., 1995; Volm et al., 1991), and paclitaxel is still used to treat NSCLC. Additionally, ABC
transporters, in particular ABCB1, can contribute to drug resistance in other cancers (Goldstein
et al., 1989; Sharom, 2008), potentially making our findings applicable to a wide variety of
cancers.
Here too, we see how AUY922 treatment simplifies the heterogeneity in the A549 culture
populations when the MDR phenotype is induced. In control cultures that received MDR
induction with paclitaxel, four populations of cells emerged in terms of ABCB1 and ABCC1
surface expression. On the other hand, AUY922 treatment reduced heterogeneity in the cultures
in a dose dependent manner, such that the cultures became increasingly double negative for
ABCB1 and ABCC1 expression. This is further support for the hypothesis that HSP90 inhibition
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can reduce heterogeneity in cancer cell populations such that they are less likely to become drug
resistant.
When it was discovered that ABC transporters drive multidrug resistance in cancer,
numerous pharmacological inhibitors were developed to limit ABC transporter driven multidrug
resistance (Robey et al., 2018). However, clinical evaluations of these inhibitors failed to
demonstrate any benefit. This was later determined to be because most of these inhibitors only
targeted a single ABC transporter at a time, and it is now suspected that expression of multiple
ABC transporters is necessary to confer multidrug resistance in cancer (Robey et al., 2018).
Furthermore, these drugs were not well tolerated in combination with chemotherapy (Robey et
al., 2018). Our flow cytometry experiments suggest that it is possible to get around some of these
problems by using AUY922 to remove cell surface expression of two major ABC transporters
thought to confer multidrug resistance in a variety of cancers, including NSCLC. If ABCB1 and
ABCC1 are not expressed on the cell surface, they cannot be expected to play a role in efflux
dependent multi drug resistance.
The down regulation of ABCB1 and ABCC1 on the surface of A549 cells treated with
AUY922 may also explain a relatively common side effect of this drug observed in clinical trials.
A frequently reported adverse effect of AUY922 is various visual disturbances, and these occur
most often in treatment cohorts receiving the highest dose of AUY922 (Bendell et al., 2015; Doi
et al., 2014; Felip et al., 2018; Johnson et al., 2015; Kong et al., 2016; Seggewiss-Bernhardt et
al., 2015; Sessa et al., 2013). Others have postulated that this might be related to a certain
sensitivity of the retina to AUY922 (Kong et al., 2016; Zhou et al., 2013), however these
investigators did not provide any direct cellular mechanism relevant to retinal physiology to
explain this sensitivity. The blood retinal barrier (BRB) is a privileged site in the body. As such
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it contains high expression of ABC transporters including ABCB1 and ABCC1 (Chapy et al.,
2016) that not only protect the retina from xenobiotic insult, but also govern multiple biological
gradients important for normal function. Application of high doses of AUY922 in clinical trials
may be down regulating ABC transporter expression in the retina and altering its ability to
properly maintain certain gradients, leading to changes in vision (Bendell et al., 2015;
Piotrowska et al., 2018; Sessa et al., 2013). Even though our work is in a different tissue type,
our results support this hypothesis when considering that almost all tissues in the human body
utilize ABC transporters to some degree. Changes in vision are not likely due to apoptosis, as
clinical trials report visual changes are reversible once AUY922 treatment is removed. However,
this can only be definitively confirmed by studies evaluating ABC transporters in retinal tissue
treated with AUY922.
Overall, the recent evidence that some treatment approaches may incidentally enable the
metastatic cascade (Kajiyama et al., 2007; Karagiannis et al., 2017; Volk-Draper et al., 2014) and
the persistence of drug resistant relapse after current treatment methods(Garraway & Janne,
2012) demands new, rational, treatment strategies that can curtail the emergence of metastatic
and drug resistant cancer phenotypes simultaneously. The work presented in this chapter points
to AUY922 as a possible drug candidate to accomplish this in NSCLC. We demonstrate that a
single treatment with AUY922 at a relatively low, clinically appropriate dose can reduce
phenotypic changes associated with both metastasis and efflux dependent drug resistance in
A549 cells. These changes can be maintained even when potent inducers of metastatic and drug
resistant phenotypes is applied. Additionally, we used AUY922 treatments in combination with
drugs that are currently used to treat NSCLC, making a case that low dose pretreatment with
AUY922 may prevent undesirable changes related to metastasis and drug resistance that has
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been associated with conventional cytotoxic therapy like paclitaxel (Datta et al., 2017; Kajiyama
et al., 2007; Karagiannis et al., 2017; Volk-Draper et al., 2014). This is reasonable for a clinical
setting since other clinical trials using AUY922 at much higher doses have shown it to be well
tolerated. Though some studies have shown AUY922 to be less well tolerated when paired with
some conventional therapies (Seggewiss-Bernhardt et al., 2015), since we are arguing that lower
doses should be used, tolerability can be expected to improve. Finally, we show circumstantial
evidence that HSP90 inhibition can simplify phenotypes in culture such that they are less prone
to providing heterogeneity for Darwinian processes to act on and drive tumor progression.
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CHAPTER 3: CONCLUSIONS

Reflection
The exact role HSP90 plays in nature has been the center of considerable debate ever
since drugs were first developed to target HSP90’s activity decades ago. Targeting HSP90 in
cancer came with heavy skepticism considering it is necessary for proper function of normal
cells. These concerns have largely been put to rest as advances in the field have demonstrated
that HSP90 inhibitors are specific to their target and accumulate in neoplastic tissue. These two
highly desirable traits that are not easily found in other cancer drugs certainly suggests that
HSP90 inhibitors should find their way into the cancer treatment process one way or another.
Our objective was to unite HSP90 inhibition in reducing the evolution of both metastatic
and drug resistant features at a single relatively low dose. This is in contrast to other studies that
investigated HSP90 inhibitors in deconstructing either drug resistance or metastasis, but not both
simultaneously (Whitesell et al., 2014) (Chong et al., 2019; Nagaraju et al., 2015). We also
wanted to study a drug resistance mechanism that could be widely applied to many cancers, such
as ABC transporter driven drug resistance, which is distinct from previous studies (Whitesell et
al., 2014).
Overall, we were successful in achieving our objective. We found that HSP90 inhibition
with AUY922 at a single low dose could pointedly restrict metastatic and ABC transporter
driven drug resistance features in A549 cells. This has strong implications for treatment of
NSCLCs since these cancers are known to rapidly develop metastasis and efflux dependent drug
resistance (Berger et al., 2005; Gabor et al., 2004; Oshika et al., 1998; Ota et al., 1995; Shanker
et al., 2010; Sosa Iglesias et al., 2018; Volm et al., 1991). Furthermore, the ability to use one
drug at low doses to curtail both of these features may increase the durability of treatment while
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also improving the quality of life for cancer patients during treatment.
Study Weaknesses
While we were effective at demonstrating HSP90 inhibition with AUY922 restricted
development of metastatic and drug resistant phenotypes, our work has some weaknesses. First,
we only demonstrated our findings in a single lung cancer cell line. We did some preliminary
studies in H596 cells, another lung cancer cell line, but we could not get the same results. This
may be because H596 cells were relatively insensitive to HSP90 inhibition with AUY922, with
an EC50>100nM according to our measurements. This suggests these cells are not as dependent
on HSP90 as A549 cells are for viability. This may make the changes we document here in terms
of cell adhesion and ABC transporters with AUY922 treatment exclusive to cancers that have a
greater dependence on HSP90 to maintain cellular functions. In terms of cancer treatment, this
may mean that in order to maximize the success of AUY922 in the clinic, patients should be
stratified according to the dependence their cancers have on HSP90 in maintaining cancer
hallmarks. Taking biopsies at different tumor regions and assessing the level of oncogene
interaction with HSP90 via a co-immunoprecipitation assay optimized for the clinic could
accomplish this. The more oncogenes that are associated with HSP90, the more likely a patient
may benefit from HSP90 inhibitor therapy.
Another putative weakness is that this work lacks reproduction in an in vivo setting. We
say putative here because as pointed out by others (Robey et al., 2018), one major confounding
factor in delineating the relationship between multi drug resistant cancers and ABC transporters
was that normal tissues and infiltrating immune cells that make up the tumor stroma also express
ABC transporters, making it difficult to accurately assess changes in ABC transporter expression
specifically occurring in neoplastic tissue. Therefore, it was reasonable to begin studying how
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HSP90 inhibitors like AUY922 alter ABC transporters in vitro since this had never been studied
before. However, the assertions made in this piece are significantly weaker without reproducing
our results in vivo.
Contributions to the Field and Future Directions
Despite its weaknesses, this work has made some significant contributions to the field of
medicine and cancer biology. Since our approach was relatively straightforward using very basic
cell culture techniques, numerous future studies can be developed from these findings.
Moreover, A549 cells are well studied and accessible to most research universities across the
country, adding to the utility of the work presented here.
As previously stated, manipulating ABC transporters in multidrug resistant cancers has
been attempted in the past with small molecule inhibition, but has come up short in delivering
clinical efficacy (Robey et al., 2018). Here we show that it is possible to simply remove ABC
transporters from the cell surface with AUY922, neutralizing their ability to efflux drugs from
A549 NSCLC cells. Other cancer types prone to ABC transporter driven drug resistance should
be studied for down regulation in ABC transporters when exposed to low doses of AUY922.
These would include colorectal, pancreatic, liver, and breast cancers to name a few (Begicevic &
Falasca, 2017). Additionally, other HSP90 inhibitors should be explored for this effect as well.
HSP90 inhibitors like AUY922 that do not require dissolution in DMSO should be the primary
focus since DMSO can induce ABC transporter expression (Nishimura, Ueda, & Naito, 2003).
The influence AUY922 has on ABC transporters in A549 cells shown in this work should
be investigated in more detail to develop strategies to apply this effect in normal tissues. The
ability to manipulate ABC transporter expression in normal tissues is relevant to medicine since
it may improve bioavailability and tissue penetration of pharmacological therapies. For example,
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a reason some drugs are not orally bioavailable is due to ABC transporter expression in the gut
lining that pumps drugs back into the lumen before they can reach the basolateral membrane and
cross into the bloodstream, significantly reducing the therapeutic effect of some drugs (Dietrich,
Geier, & Oude Elferink, 2003). Furthermore, the blood brain barrier of the central nervous
system is covered in ABC transporters that serve to protect it from xenobiotic insult, but
becomes a significant obstacle for physicians attempting to apply pharmacological therapy to the
central nervous system (Begley, 2004). It is unlikely that normal tissue will behave in the same
way as neoplastic tissue when exposed to AUY922 because neoplastic tissue contains more
activated HSP90. But if a mechanism can be identified in A549 cells that drives the reduced
MDR phenotype when exposed to AUY922, that mechanism can be explored in detail in normal
tissue and potentially exploited to down regulate ABC transporters to aid therapies in reaching
their target tissue.
Finally, this work is distinct from other cancer research in that it successfully
demonstrates the possibility of diminishing metastasis and drug resistance together, at the same
dose, with a single drug. This is a significant discovery since the cellular mechanisms driving
metastasis and drug resistance we show here are not known to operate through shared cellular
mechanisms. Here we show evidence they are linked by HSP90. A549 cell xenograft studies in
mice should be carried out immediately to evaluate whether the changes in metastatic and drug
resistant features we observed with AUY922 in vitro are carried over in vivo. AUY922 should be
administered to mice in low doses paired with paclitaxel or other chemotherapies in a clinically
achievable treatment schedule. Mice should be followed for several months to evaluate
progression of their tumors. Other HSP90 inhibitors that have shown success in low doses, such
as ganetespib, should also be evaluated in parallel. If successful, this makes a strong case for
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designing human clinical trials using HSP90 inhibitors in low doses to simultaneously restrict
metastasis and drug resistance from developing in a patient’s tumor.
Final Remarks
Clinical trials have demonstrated that AUY922 and other HSP90 inhibitors are more
potent in combination with other conventional chemotherapies (Bendell et al., 2015; Johnson et
al., 2015; Kong et al., 2016; Modi et al., 2011) than by themselves (Doi et al., 2014; Piotrowska
et al., 2018; Seggewiss-Bernhardt et al., 2015). This is uncannily similar to the the antibiotic,
clavulanic acid. Clavulanic acid is a weak antibiotic on its own (Brumfitt & Hamilton-Miller,
1984), but when combined with beta-lactam antibiotics, significantly potentiates their action
through inhibition of microbial derived lactamases. Lactamase activity is an adaptive mechanism
microbes developed to fight beta lactam producing fungi and is the main source of treatment
failure of beta lactam antibiotics (Sykes, 2010). This was a significant problem until clavulanic
acid was discovered, and it essentially revived a whole class of antibiotics that were rapidly
becoming obsolete. Now, clavulanic acid is routinely used in combination with beta lactam
antibiotics to successfully treat microbial infections resistant to beta lactam monotherapy.
The heat shock response, which is considered an adaptive response to cellular stress
(Schlesinger, 1990), is known to play a significant role in cancer progression (Calderwood &
Gong, 2016). Furthermore, a major chaperone protein integral to the heat shock response,
HSP90, appears to support the evolution of metastatic and drug resistant cancers, which are
responsible for the bulk of treatment failure. This is further strengthened when considering that
HSP90 has multiple protein clients in each of the original six hallmarks of cancer (Hanahan &
Weinberg, 2000) (Figure 4) including the hallmarks of “resistance to apoptosis” and “activation
of invasion and metastasis”. The results presented here demonstrate that AUY922, a potent
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HSP90 inhibitor, can limit some of the phenotypic changes associated with metastatic and drug
resistant cancers simultaneously. To date, there is not a class of drugs specifically used to
suppress the evolution of metastatic and drug resistant phenotypes in cancer like there have been
for the evolution of drug resistant microbial infections in the case of clavulanic acid. Could
AUY922, and other HSP90 inhibitors, be operating like clavulanic acid by targeting an adaptive
mechanism that many cancers appear to rely on to evolve metastatic and drug resistant
phenotypes, both of which are responsible for treatment failure? Our results in addition to others
certainly support that notion. Perhaps it is time to begin taking a closer look at using HSP90
inhibitors to shape the cancer, rather than kill it, to improve cancer treatment outcomes.
It is also possible that HSP90 inhibition in cancer has less to do with directly
hamstringing HSP90’s adaptive function and more to do with reducing ITH and revealing
evolutionary “dead ends” stored in HSP90’s capacitor function. Since HSP90 chaperones clients
in every core cancer hallmark, limiting its function significantly reduces a cancer’s ability to lean
on any individual cancer hallmark to maintain survival since their gene products would all be
simultaneously compromised (Figure 15). This may force the emergence of phenotypes that are
far less aggressive and may actually represent evolutionary “dead ends”. In terms of the natural
course of cancer, this refers to phenotypes that are less metastatic and drug resistant. We have
some evidence for that here in this work. Another possible evolutionary “dead end” could be
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Figure 15: Hypothetical Illustration of HSP90 Inhibition Crippling Tumor Evolution
As in previous illustrations, HSP90 is shown orchestrating the cancer hallmarks in order to
promote evolution of three tumor phenotypes (orange, pink purple), with enlarged colored boxes
to denote the collective level of dependence the tumor has on the cancer hallmarks (LEFT).
HSP90 inhibition shuts down the cancer hallmarks simultaneously, denoted by the shrunken
colored boxes, bringing the tumor to a new state that is less able to evolve new neoplastic
characteristics (sea green crosshatches). This may reveal evolutionary “dead ends” hidden in the
cancer’s genome, making the neoplasm more vulnerable to selective pressures it previously
evolved to thwart, such as the immune system and chemotherapy.
resensitization of cancer cells to the immune system. There is already some evidence for this
forming in studies demonstrating that ganetespib can sensitize cancer cells to T-cell mediated
anti-tumor responses (Mbofung et al., 2017), though they do not discuss their findings in terms
of tumor evolution. Revealing these evolutionary “dead ends” could fundamentally alter the
trajectory of tumor evolution, perhaps even resulting in sustained tumor remission.
Given the complex nature of the mechanisms that drive metastasis and drug resistance in
cancer, HSP90 inhibitors are unlikely to be a silver bullet. If we reframe cancer as a moving
target that strives to evolve metastatic and drug resistant features over time according to the
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theory of tumor evolution, we may discover alternative ways to prevent these features from
manifesting in the first place. Therefore, more work should be dedicated to identifying cellular
mechanisms and microenvironmental factors that drive both metastasis and drug resistance from
the earliest stages of carcinogenesis to the final stages of advanced disease. If possible, we
should develop drugs against single targets that are essential in driving both metastasis and drug
resistance so as to leave room for combination therapy with cytotoxic agents to control tumor
growth. Some investigators have already started working on this idea (Cao et al., 2018). This
may not turn out to be the most effective way to kill the cancer outright, but if we can prevent
drug resistance and metastasis from developing, there is a good chance we can control the
disease and extend the lives of cancer patients. Even more, we may learn that approaching cancer
treatment in this way may not require the levels of cytotoxic therapy currently recommended for
cancer treatment, thus significantly improving the quality of life for patients during the treatment
process.
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